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Abstract
Neuropathological follow-up of patients with Alzheimer’s disease (AD) who participated in the first clinical trial of
Amyloid-β 42 (Aβ42) immunization (AN1792, Elan Pharmaceuticals) has shown that immunization can induce
removal of Aβ42 and Aβ40 from plaques, whereas analysis of the cerebral vessels has shown increased levels of
these Aβ peptides in cerebral amyloid angiopathy (CAA). Aβ43 has been less frequently studied in AD, but its
aggregation propensity and neurotoxic properties suggest it may have an important pathogenic role. In the current
study we show by using immunohistochemistry that in unimmunized AD patients Aβ43 is a frequent constituent of
plaques (6.0% immunostained area), similar to Aβ42 (3.9% immunostained area). Aβ43 immunostained area was
significantly higher than that of Aβ40 (2.3%, p = 0.006). In addition, we show that Aβ43 is only a minor component
of CAA in both parenchymal vessels (1.5 Aβ43-positive vessels per cm2 cortex vs. 5.3 Aβ42-positive vessels, p = 0.03,
and 6.2 Aβ40-positive vessels, p = 0.045) and leptomeningeal vessels (5.6% Aβ43-positive vessels vs. 17.3% Aβ42-
positive vessels, p = 0.007, and 27.4% Aβ40-positive vessels, p = 0.003). Furthermore, we have shown that Aβ43 is
cleared from plaques after Aβ immunotherapy, similar to Aβ42 and Aβ40. Cerebrovascular Aβ43 levels did not
change after immunotherapy.
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Introduction
Alzheimer’s disease (AD) is characterized by the extra-
cellular accumulation of the Amyloid-β (Aβ) protein in
the brain parenchyma as plaques and in cerebrovascular
blood vessel walls as cerebral amyloid angiopathy
(CAA), and the intraneuronal accumulation of the tau
protein. It is hypothesized that CAA is caused by dys-
functional Aβ elimination: a process that may include
enzymatic degradation, receptor-mediated clearance
across the blood-brain barrier (BBB), and drainage with
interstitial fluid along perivascular pathways [33]. Block-
age of these pathways may lead to aggregation of Aβ in
the vessel walls as CAA [10, 22]. In a subset of CAA pa-
tients, Aβ deposits in both arteries and arterioles, and
capillaries (CAA type 1), whereas more commonly,
cerebrovascular Aβ accumulation is restricted to larger
vessels, without affecting capillaries (CAA type 2) [34].
The occipital lobe is most frequently and severely
affected by CAA [1, 2], and leptomeningeal vessels are
more frequently affected compared to parenchymal
vessels [1, 27].
Aβ is a peptide consisting of 38 to 43 amino acids, with
Aβ40 and Aβ42 being the most-studied Aβ isoforms.
Aβ42 is a major constituent of plaques, whereas some
studies show that Aβ40 is the predominant species in
CAA [9, 28]. Aβ is produced through cleavage of the
amyloid precursor protein (APP) by γ-secretase, which is
predominantly initiated at ε cleavage sites situated after
Leu49 or Thr48. The resulting Aβ49 or Aβ48 are sequen-
tially cleaved in increments of three amino acids, which
leads to the production pathways Aβ49→Aβ46→
Aβ43→Aβ40 and Aβ48→Aβ45→Aβ42 [7, 26, 32].
Only relatively recently it was found that in addition to
Aβ40 and Aβ42, also Aβ43 may play a major role in AD,
as plaques contain more Aβ43 than Aβ40 [13, 29, 36].
Interestingly, although Aβ43 seems to be a major
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component of plaques, no significant levels of Aβ43 have
been reported in CAA [13, 36].
The amyloid cascade hypothesis states that aggregation
of Aβ into plaques is the initial event in AD, followed by
the formation of neurofibrillary tangles, and synaptic
and neuronal loss leading to cognitive decline [17].
Therefore, in the past two decades, much attention has
been directed towards the possibilities of Aβ immuno-
therapy to remove Aβ from the brain. Both active and
passive Aβ immunotherapy approaches have been shown
to be effective in the removal of plaques from the human
brain, although so far the effects on slowing or prevent-
ing cognitive decline have been mainly disappointing
[12, 31, 35].
In the first clinical trial of Aβ immunization, which
started in 2000, patients with mild to moderate AD were
actively immunized with synthetic full-length Aβ42
(AN1792, Elan Pharmaceuticals [4]). Post-mortem neuro-
pathological examination of 12 immunized AD patients
showed variable, sometimes extensive, clearance of Aβ
plaques from the cerebral cortex [5, 20, 23, 30]. Interest-
ingly, decreases in parenchymal amyloid were associated
with an increased vascular amyloid burden [21, 23, 24].
This lead to the hypothesis that immunization results in
solubilization of Aβ plaques, followed by perivascular
drainage of the solubilized Aβ that leads to the develop-
ment of CAA [5].
In this study, we have investigated the expression of
Aβ43 in parenchymal plaques and CAA in the AD brain.
Furthermore, we assessed the effects of Aβ42 immuno-
therapy on Aβ43 accumulation, both in plaques and the
cerebral blood vessels, by post-mortem examination of a
unique cohort of patients who were included in the first
AN1792 clinical trial. Aβ43 deposition was analysed in
relation to Aβ40 and Aβ42, to generate more insight
into the relative deposition of Aβ43 in plaques and CAA
and to study the effects of immunotherapy on the distri-
bution of Aβ43 in AD brains. Analysing the fate of
different Aβ isoforms following immunotherapy may
provide insight into potential differences in clearance
efficiency.
Materials and methods
Sample cohort
Sixteen Alzheimer’s disease patients immunized against
Aβ42 (AN1792, Elan Pharmaceuticals Inc. [4]), denoted
iAD, with confirmed post-mortem neuropathological AD
diagnosis were examined for the current study. Twenty-
one non-immunized AD cases (AD) from the South
West Dementia Brain Bank (SWDBB Bristol, UK) were
included for comparison. The AD and iAD groups were
matched as far as possible for age, gender, and APOE
genotype, but disease duration differed between the
groups (Table 1). The study of the iAD cohort was per-
formed under the ethical approval from Southampton
and South West Hampshire Local Research Ethics Com-
mittees (Reference No: LRC 075/03/w). The use of the
SWDBB tissue was covered by the ethical approval from
North Somerset and South Bristol Hampshire Local
Research Ethics Committees (Reference No: REC 08/
H0106/28 + 5).
Immunohistochemistry
Four micrometer-thick paraffin sections of the middle
temporal gyrus were used for immunohistochemistry.
After rehydration and antigen retrieval, including neat
formic acid pre-treatment and heat-induced epitope
retrieval, sections from AD and iAD cases were stained
with rabbit-anti-human Aβ43 (IBL, Fujioka, Japan; cat.
no. 18583, 0.5 μg/ml). Furthermore, sections were
stained with mouse-anti-human Aβ42 (clone 21F21, 1:
4000) and mouse-anti-human Aβ40 (clone 2G3, 1:4000),
Table 1 Characteristics of the groups
AD iAD p
N 21 16
Sex (% male) 48 56 0.60a
Duration Dementia (years, mean ± sd) 8.5 ± 3.3 11.9 ± 4.5 0.02b
n/a: n = 4
APOE genotype 2,2 or 2,3: 15% 2,2 or 2,3: 0% 0.45a
3,3: 15% 3,3: 25%
3,4: 55% 3,4: 50%
4,4: 15% 4,4: 25%
n/a: n = 1 n/a: n = 4
Age at death (years, mean ± sd) 78.0 ± 7.5 79.2 ± 8.4 0.64b
Survival time after immunization (months, mean ± sd) N.A. 91.9 ± 57.7
Abbreviations: AD Alzheimer’s disease patients, iAD immunized Alzheimer’s disease patients, Aβ amyloid-β, N.A not applicable. n/a: not available.
Analysed by aPearsons’ chi-square and bt-test.
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both provided by Elan Pharmaceuticals (South San Fran-
cisco, CA, USA) [16]. Binding of biotinylated secondary
antibody (goat-anti-rabbit or rabbit-anti-mouse, DAKO,
Glostrup, Denmark) was detected with the Vectastain
ELITE ABC kit (Vector Laboratories, Peterborough, UK),
using 3,3′ diaminobenzidine (DAB) as chromogen and
0.05% hydrogen peroxide as substrate. Sections were
mounted in DePex (BDH Laboratory Supplies, Poole, UK).
Antibody specificity
We tested the specificity of the antibodies by immunoas-
says. First, 25 nM of synthetic Aβ43 (Anaspec, Fremont,
CA, USA; cat. no. AS-25357), Aβ42 (Bachem, Buben-
dorf, Switzerland; cat. no. H-1368), and Aβ40 (QCB,
Hopkinton, MA, USA; cat. no. 20–1000), all diluted in
NaHCO3 (pH 9.6), were coated overnight at 4 °C on a
96-wells plate. Then, the plate was washed 3 times with
PBS containing 0.05% Tween20 and blocked 1 h at room
temperature (RT) with PBS containing 1% BSA. Wells
were then incubated with rabbit-α-Aβ43 (1:500), 21F12
(1:10000), 2G3 (1:3000), or biotinylated pan-Aβ antibody
(clone 4G8, Biolegend, San Diego, CA, USA; cat. no.
800701, 1:2500), diluted in PBS containing 1% BSA.
After 2 h incubation at RT and subsequent washing, wells
were incubated for 1 h with a secondary antibody (goat-α-
rabbit HRP, rabbit-α-mouse HRP, or streptavidin-HRP) at
RT. As a substrate, 100 μl of 3,3′,5,5′-tetramethylbenzi-
dine (TMB) solution was added, and the reaction was
stopped with 50 μl of 1M H2SO4. Optical density (OD)
values were measured at 450 nm using a Tecan Infinity
F50 plate reader.
Quantification of Aβ load
Whole sections were scanned at a 20x objective magnifi-
cation using a V120 virtual slide microscope (Olympus,
Tokyo, Japan). Thirty regions of interest (ROIs) were se-
lected in a zigzag sequence along the cortical ribbon, to
ensure representation of cortical layers, in similar ana-
tomical regions for each case. ROIs were analysed using
Fiji software (version 1.51) to obtain a protein load de-
fined as percentage of immunostained area, as in previ-
ous studies [30, 37]. The immunostained area
predominantly represents the amount of Aβ accumu-
lated in the brain parenchyma as plaques, and is there-
fore referred to as such, although CAA might have made
a small contribution to this value.
Quantification of CAA
Quantification of CAA was performed on the entire
section at a 10x objective magnification. The grade of
Aβ staining was scored in each leptomeningeal vessel as
follows: fully affected by CAA (full circumference and
thickness), partially affected by CAA, or not affected by
CAA, and the data were expressed as percentage stained
vessels (%). In the cortex, blood vessels fully affected by
CAA (full circumference and thickness) or partially af-
fected by CAA were counted, and the data were pre-
sented as the number of affected vessels per cortical grey
matter area (cm2), as previously performed in our group
[5]. For analyses, fully and partially stained vessels were
combined into one group (e.g. ‘positive vessels’), as no
differences between fully and partially stained vessels
were detected.
Statistical analysis
Data analysis was performed using IBM SPSS Statistics 25
(Armonk, NY, USA) and GraphPad Prism 5 (La Jolla, CA,
USA). Normality of data was assessed using D’Agostino &
Pearson test. The protein loads of the three Aβ isoforms
were compared using a Kruskall-Wallis test and post-hoc
Mann Whitney U-test with Bonferroni correction for mul-
tiple analysis. The numbers of vessels in AD patients
affected by Aβ43, Aβ42, and Aβ40 were analysed using
paired t-tests. Correlations between Aβ isoform length and
Aβ load in plaques and CAA was assessed using Spear-
man’s test. The protein loads and total numbers of positive
vessels for each Aβ isoform were compared between AD
and iAD cases using two-sample two-sided t-test or
nonparametric Mann–Whitney U-test (depending on the
normality of the data). The correlations between total num-
bers of leptomeningeal and parenchymal vessels affected by
the three Aβ isoforms were assessed in the combined
cohort of AD and iAD patients using Spearman’s test. The
threshold for statistical significance was set at 5%.
Results
Antibody specificity
The immunoassays showed that the anti-Aβ43 antibody
specifically recognized Aβ43 (Fig. 1a). Interestingly, the
21F12 antibody detected both the Aβ42 peptide, and, to
a much lesser extent, the Aβ43 peptide (Fig. 1b). The
2G3 antibody was specific for Aβ40 (Fig. 1c). Detection
using the pan-Aβ 4G8 antibody was used to confirm that
all three Aβ peptides were coated in similar amounts
(Fig. 1d).
Aβ peptides in plaques in AD cases
Qualitative assessment of reactivity of the different Aβ
antibodies in the middle temporal lobe showed that
anti-Aβ43 and anti-Aβ42 antibodies immunolabeled
diffuse and dense-core plaques, whereas Aβ40 detec-
tion was largely confined to plaque cores (Fig. 2a-f).
Comparison of the area immunostained by each Aβ
antibody showed that Aβ43 immunostaining (median
6.0%) covered a larger area of the cortex compared to
Aβ40 (median 2.3%, p = 0.006). The area covered by
Aβ42 immunostaining (median 3.9%) was also signifi-
cantly higher than the area covered by Aβ40 (p =
Jäkel et al. Acta Neuropathologica Communications           (2019) 7:141 Page 3 of 11
0.036), but did not differ from the Aβ43 immuno-
stained area (p = 0.17; Fig. 2g).
Aβ peptides in CAA in AD cases
Aβ43 was, like Aβ42 and Aβ40, detected in leptomenin-
geal and parenchymal blood vessels as illustrated in Fig. 3.
Quantification of vascular staining revealed lower num-
bers of parenchymal vessels affected per cm2 by Aβ43
(median 1.5) compared to Aβ42 (median 5.3, p = 0.03) and
Aβ40 (median 6.2, p = 0.045, Fig. 4a). Similarly, the per-
centage of Aβ43-affected leptomeningeal vessels (median
5.6) was significantly lower compared to Aβ42 (median
17.3, p = 0.007) and Aβ40 (median 27.4, p = 0.003). The
percentage of leptomeningeal vessels in which Aβ42 was
detected was significantly lower than the percentage of
Aβ40-affected vessels (p = 0.012) (Fig. 4b-e).
Peptide length correlates to Aβ load
A correlation was observed between Aβ peptide length and
Aβ load in plaques (Aβ43 >Aβ42 >Aβ40, rs= 0.48, p=
0.0002, Fig. 5a). Interestingly, an inverse correlation was ob-
served between Aβ peptide length and the numbers of both
parenchymal (Aβ40 >Aβ42 >Aβ43, rs=− 0.39, p= 0.003,
Fig. 5b) and leptomeningeal (rs=− 0.42, p= 0.001, Fig. 5c)
vessels positive for the different Aβ isoforms.
Effect of immunotherapy on Aβ peptides in plaques
Quantification of Aβ in the iAD cases showed a reduc-
tion in median immunostained area values by a factor of
5.5 for Aβ43 (AD = 6.0; iAD = 1.1; p < 0.0001), a factor of
2.3 for Aβ42 (AD = 3.9; iAD = 1.7; p = 0.0006), and factor
of 2.5 for Aβ40 (AD = 2.3; iAD = 0.9; p = 0.004), com-
pared to the unimmunized AD cases (Fig. 6a-i).
Effect of immunotherapy on Aβ peptides in CAA
There was substantial variation in the numbers of
Aβ-positive vessels between iAD cases. No significant
differences for the numbers of parenchymal vessels
affected by Aβ43, Aβ42, and Aβ40 were detected be-
tween non-immunized and immunized AD cases
Fig. 1 Specificity of anti-Aβ antibodies. The anti-Aβ43 antibody specifically recognizes Aβ43 (a). The 21F12 antibody also recognizes Aβ43, in
addition to Aβ42 (b). The 2G3 antibody is specific for Aβ40 (c). Detection with the 4G8 antibody shows that the different Aβ isoforms are present
in comparable amounts and bind to the plate with similar affinity (d). Data are presented as mean (standard deviation)
Fig. 2 Parenchymal Aβ load in AD cases. Representative images of parenchymal tissue stained by antibodies directed against Aβ43 (a), Aβ42 (b),
and Aβ40 (c) at 20x objective magnification. Indicated areas are shown at higher magnification (d-f). A significantly larger portion of the cortex is
immunostained by the Aβ43- and Aβ42-specific antibodies compared to the Aβ40-specific antibody (g). The cases shown in a-f are
representative of the median immunostained area as plotted in g. Box plot shows median values with the 25th and 75th percentile as
boundaries and whiskers indicating minimum and maximum values. Scale bar = 50 μm (upper panel) or 20 μm (lower panel). *p≤ 0.05; **p≤ 0.01
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(Fig. 7a). Similarly, no differences were observed for
the percentages of stained leptomeningeal vessels.
Median values of positive leptomeningeal vessels were
45.4% in iAD versus 27.4% in AD for Aβ40, and
45.0% in iAD versus 16.4% in AD for Aβ42, whereas
they were almost identical for Aβ43 (3.4% versus
2.9%). Analysis of the complete cohort (combining
AD and iAD cases) showed that the numbers of
leptomeningeal or parenchymal vessels affected by
either Aβ43, Aβ42, or Aβ40 were strongly correlated
to each other, with rs values between 0.57 and 0.85,
and p < 0.001 for all correlations (Fig. 8). These corre-
lations were also observed in separate correlation
analysis of the unimmunized AD cohort (rs values be-
tween 0.63 and 0.88, and p values between < 0.001
and 0.015). Similarly, 14 out of 15 peptide correla-
tions were significant in the immunized AD cohort
(rs values between 0.55 and 0.85, and p values be-
tween < 0.001and 0.04), the relation between lepto-
meningeal Aβ43 and parenchymal Aβ42 being the
only exception (rs = 0.44, p = 0.11).
Discussion
In this study, we have explored the relatively little studied
Aβ43 peptide and compared its cerebral expression levels
in AD cases to those of Aβ42 and Aβ40, and studied the
effects of active Aβ42 immunotherapy. Aggregation pro-
pensity [15] and neurotoxic properties [8] of Aβ43 have
been defined as indicators for an important pathogenic role
of Aβ43 in AD. Knock-in mice containing a presenilin-1
R278I mutation overproduced Aβ43, and crossing these
mice with APP transgenic mice resulted in offspring with
elevated Aβ43 levels, impaired short-term memory, and ac-
celerated amyloid pathology [29]. Our results in AD cases
also indicated that large amounts of Aβ43 accumulated into
plaques, to a degree that is similar to that of Aβ42 accumu-
lation. The cerebrovascular expression of Aβ43 has received
sparse attention in literature. It has been demonstrated in
brain tissue of five AD patients that Aβ43 and Aβ42 are
absent from CAA [13]. Using mass spectrometry, it was
demonstrated that Aβ43 levels in SDS preparations of brain
tissue, containing blood vessels or parenchymal deposits
other than plaque cores, are substantially lower compared
to Aβ40 and Aβ42 [36]. Together, these data suggested that
Aβ43 does not readily accumulate in the vasculature. In
our study, however, we observed cerebrovascular accumu-
lation of Aβ43 in AD, although less vessels were positive
for Aβ43 compared to Aβ42 and Aβ40. Of note, despite
low levels of cerebrovascular Aβ43, we observed a high
abundance of Aβ43 in plaques. Interestingly, we found a
correlation between Aβ peptide length and plaque load
(Aβ43 >Aβ42 >Aβ40), indicating that longer Aβ peptides
have an increased tendency towards accumulation in the
brain parenchyma. In contrast, an inverse correlation was
observed between Aβ peptide length and CAA load
(Aβ40 >Aβ42 >Aβ43), suggesting that shorter peptides
Fig. 3 Representative examples of Aβ43 staining in cerebral small vessels. Aβ43-immunostaining was detected in both leptomeningeal (a, b) and
parenchymal (d, e) vessels. Some immunostained vessels were partially stained (b, e). In others, Aβ43 staining was detected in the full
circumference and thickness of the vessel wall (a, d). Many vessels were devoid of Aβ43 (c). Scale bar = 20 μm (a, b, c, e) or 50 μm (d)
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have an increased tendency to accumulate in the
cerebrovasculature.
We found a higher plaque load of Aβ43 and Aβ42
versus Aβ40 (Fig. 2g), which likely drives the positive
association between plaque load and peptide length
(Fig. 5a). It is known that Aβ42 and Aβ40 differ in
that Aβ40 is mainly located in plaque cores whereas
Aβ42 is present also in the diffuse component of pla-
ques [14], and the immunohistochemical pattern of
Aβ43 in our study largely resembles that of Aβ42
(Fig. 2). It is possible, though, that a non-significant
number of plaques contain more Aβ43 than the other
isoforms, or that the distribution of Aβ43 extends be-
yond the area stained for Aβ42 in some plaques. This
Fig. 5 Plaque and CAA severity correlate to Aβ peptide length. Analysis of plaque and CAA severity in brain tissue of AD patients immunostained
for Aβ43, Aβ42, and Aβ40 shows that Aβ peptide length correlates to plaque load (a). An inverse correlation between Aβ peptide length and
both the number of Aβ-affected parenchymal vessels (b) and leptomeningeal vessels (c) is observed
Fig. 4 Aβ peptides in the cerebrovasculature of AD cases. Analysis of the numbers of parenchymal (a) and leptomeningeal (b) vessels
affected by Aβ43, Aβ42, and Aβ40 in AD cases shows significantly lower numbers of vessels affected by Aβ43 compared to the other
peptides. Images of cerebrovascular immunostaining of Aβ43 (c), Aβ42 (d), and Aβ40 (e) in the same cortical area of an AD case. Box
plots show median values with the 25th and 75th percentile as boundaries and whiskers indicating minimum and maximum values. Scale
bar = 50 μm. *p ≤ 0.05; **p ≤ 0.01
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point has not been addressed in this study and re-
quires meticulous analysis of expression patterns in
individual plaques, which was outside the scope of
this study. Similarly, it is likely that Aβ40, Aβ42, and
Aβ43 are – a least to some extent – colocalised in
blood vessel walls. Future studies including double or
triple Aβ staining in brain tissue of AD and iAD
patients are needed to provide insight into the exact
co-localisation of various Aβ isoforms in plaques and
CAA.
One hypothesis to explain the relatively low abun-
dance of Aβ43 in the cerebrovasculature compared to
other isoforms in AD, is a more efficient Aβ43 clearance
at the BBB. Analysing the fate of Aβ43 following im-
munotherapy may provide insight in this potential
efficient clearance of Aβ43. Similar to Aβ40 and Aβ42,
the Aβ43 load in the parenchyma is decreased in re-
sponse to Aβ42 immunotherapy. This is not surprising,
as the majority of antibodies produced following
AN1792 immunization are directed against the N-
terminus of Aβ, which is shared by all three Aβ isoforms
[19]. Interestingly, despite the absence of a gross signifi-
cant difference in cerebrovascular expression of the
three peptides in the two cohorts, Aβ43 was the only
isoform that did not display the gross - yet not signifi-
cant - increase of leptomeningeal CAA that was seen for
Aβ42 (275%) and Aβ40 (165%) after immunization. This
is noteworthy, considering the fact that Aβ43 is the iso-
form that was most rigorously removed from plaques
(5.5 times lower Aβ43 load compared to a 2.3- and 2.5-
fold reduction for Aβ42 and Aβ40 respectively), indicat-
ing that following immunotherapy Aβ43 is readily
released from plaques. However, despite its increased
availability for transport towards the vasculature, Aβ43
is less prone to accumulate at the vasculature than
Aβ42. This suggests that Aβ43 might be more effi-
ciently cleared at the BBB. A potential alternative
explanation for the relatively low abundance of Aβ43
in the AD vasculature could be its high propensity to
aggregate [15, 29], which may prevent Aβ43 from
reaching the vasculature. There are, however, several
arguments against that scenario. First, if its high
Fig. 6 Effect of immunotherapy on parenchymal Aβ load. Aβ43 (a), Aβ42 (b), and Aβ40 (c) loads are significantly lower in iAD cases compared to
non-immunized AD cases. Representative images of Aβ43 (d, g), Aβ42 (e, h), and Aβ40 (f, i) load in AD (d-f) and immunized AD cases (g-i).
Box plots show median values with the 25th and 75th percentile as boundaries and whiskers indicating minimum and maximum values. Scale
bar = 100 μm. **p≤ 0.01; ***p≤ 0.001
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aggregation propensity would explain the low abun-
dance of Aβ43 in CAA, it would be expected that after
solubilization of Aβ43 from plaques, its levels in CAA
would increase. This is, however, not the case. Second,
a high aggregation propensity does not necessarily
prevent vascular accumulation of Aβ, as can be
deduced from observations on the Dutch mutant
Aβ40(E22Q) which is both very prone to aggregate
and widely observed in the cerebrovasculature in mu-
tation carriers [11, 18]. Therefore, the low abundance
of Aβ43 in CAA seems to be more consistent with our
hypothesis of a more efficient clearance of this Aβ iso-
form across the BBB.
We used immunohistochemistry to assess the antigen
load of the different Aβ isoforms. Although this is a
widely accepted method for relative protein quantifica-
tion [6, 29, 30], a possible limitation of our study is that
comparison of antigen load stained by different anti-
bodies is not fully possible. However, by carefully select-
ing thresholds for every antibody, we ensured that only
specific immunoreactivity for each antibody was cap-
tured, allowing for relative assessment of the expression
of the different Aβ isoforms. However, immunohisto-
chemistry does not yield a measure of absolute protein
levels, and the observed differences between Aβ isoforms
are relative.
Using immunoassays, we showed that the 21F12 anti-
body, often used for its assumed Aβ42-specificity, also
recognized Aβ43, albeit more weakly. This observation
has been shared and acknowledged by many researchers
through the use of the term “Aβ42(43)-specific” when
describing the 21F12 antibody. Many antibodies thought
to be specific for Aβ42 also recognize longer variants, a
fact that should be kept in mind when interpreting re-
sults obtained using such antibodies. We do not expect
that this cross-reactivity has substantially affected our
results, as the vascular and parenchymal changes of
Aβ42 accumulation due to immunotherapy have been
described before and our findings are in line with these
previous studies [5, 23].
Fig. 7 Effect of immunotherapy on cerebrovascular Aβ load. The numbers of parenchymal (a) and leptomeningeal (b) vessels affected by Aβ43,
Aβ42, or Aβ40 did not differ between AD and iAD cases. Images of cerebrovascular immunostaining of Aβ43 (c), Aβ42 (d), and Aβ40 (e) in the
same cortical area of an immunized AD case. Box plots show median values with the 25th and 75th percentile as boundaries and whiskers
indicating minimum and maximum values. Scale bar = 100 μm
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Earlier studies in our cohort have shown a decrease in
the number of plaques and an increase of vascular Aβ42
and Aβ40 in the early years after immunotherapy [5, 30].
We confirmed significantly lower levels of Aβ42 and
Aβ40 in plaques of iAD patients compared to unimmu-
nized patients. However, we did not detect significantly
higher numbers of Aβ42- and Aβ40-affected vessels in
the immunized group. A possible explanation might be
that in the current study only one brain region, the mid-
dle temporal gyrus, was included in the analysis, whereas
in earlier publications multiple brain regions were stud-
ied, including the frontal, middle and temporal gyrus,
and thus we might be less powered to detect these
changes. Another, more important, explanation may be
that, in the current study, we have expanded the iAD
population with patients who survived longer after
immunization than in previous studies. It is possible that
the effects of active immunization on cerebrovascular
Aβ levels may be transient or less pronounced in the
long term. Indeed, we found indications of a negative
correlation between Aβ42 levels in CAA and survival
time (parenchymal Aβ42: r = − 0.605, p = 0.022; lepto-
meningeal Aβ42: r = − 0.629, p = 0.021), although the
small number of cases precludes any firm conclusion.
Another potential confounder may be that, in line with
previous observations, the extent of Aβ release from
plaques is positively associated with the level of the im-
mune response [12]. In addition, we observed a trend
towards lower levels of Aβ in CAA in cases with a strong
immune response (data not shown), indicating that, in
addition to plaque removal, immunotherapy may lead to
the removal of vascular Aβ, as has been demonstrated
before in mouse models [3, 25]. However, again, the
small number of cases and the limitation of only one
studied brain region precludes us from drawing firm
conclusions on these potential relations. Further studies
on the long-term effects of active immunization on CAA
levels are needed.
Conclusions
We show that Aβ43 is not only an important constituent
of plaques but also associated with CAA, albeit at lower
Fig. 8 The numbers of vessels affected by the different Aβ isoforms strongly correlate to each other. Parv = parenchymal vessels;
Lepv = leptomeningeal vessels
Jäkel et al. Acta Neuropathologica Communications           (2019) 7:141 Page 9 of 11
levels than Aβ42 and Aβ40, suggesting that the expression
pattern of Aβ pathology is isoform-specific. Furthermore,
neuropathological analysis from the first human immuno-
therapy study also yielded preliminary evidence that Aβ43
may be more efficiently cleared at the BBB than Aβ42 and
Aβ40, although mechanistic studies are needed to confirm
this suggestion.
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